Matthew P. Morrow

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 689 citations

Immunology, Human Papillomavirus 16, Cancer-associated Virus +17

Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from Macrophages

Zahedi Mujawar, H Rose, Matthew P. Morrow et al. · PLoS Biology · 2006 · 331 citations · Full text

Biochemistry, Natural Sciences, Human Retrovirus +15

Immunotherapy Against HPV16/18 Generates Potent T _H 1 and Cytotoxic Cellular Immune Responses

Mark L. Bagarazzi, Jian Yan, Matthew P. Morrow et al. · Science Translational Medicine · 2012 · 279 citations · Full text

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas, ShuPing Yang, Jean Boyer et al. · EClinicalMedicine · 2020 · 276 citations · Full text

A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

Kar Muthumani, Darryl Falzarano, Emma L. Reuschel et al. · Science Translational Medicine · 2015 · 249 citations · Full text